Venous thromboembolism following primary total hip arthroplasty

International Angiology

Volumn 28, Issue 3, 2009, Pages 215-221

  Hitos, K ^a   Fletcher, J P ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Arthroplasty, replacement, hip; Aspirin; Heparin, low molecular weight; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; HORMONE; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; WARFARIN; FIBRINOLYTIC AGENT;

ADULT; AGED; ARTICLE; BLEEDING; FEMALE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OPERATION DURATION; POSTOPERATIVE COMPLICATION; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; VENOUS THROMBOEMBOLISM; AUSTRALIA; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; CLINICAL PRACTICE; HIP ARTHROPLASTY; HOSPITAL READMISSION; INCIDENCE; MIDDLE AGED; MORTALITY; PRACTICE GUIDELINE; REGRESSION ANALYSIS; RISK ASSESSMENT; TIME; TREATMENT OUTCOME;

AGED; ARTHROPLASTY, REPLACEMENT, HIP; CHI-SQUARE DISTRIBUTION; FEMALE; FIBRINOLYTIC AGENTS; GUIDELINE ADHERENCE; HEMORRHAGE; HUMANS; INCIDENCE; LENGTH OF STAY; MALE; MIDDLE AGED; NEW SOUTH WALES; PATIENT READMISSION; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 69549089673     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:338S-400S.
2. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:381S-453S. (Pubitemid 351894916)
3. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA, Jr. et al. Prevention of venous thromboembolism. Chest 2001;119:132S-175S.
4. Bounameaux H. Integrating pharmacologic and mechanical prophylaxis of venous thromboembolism. Thromb Haemost 1999;82:931-937.
5. Eskander MB, Limb D, Stone MH, Furlong AJ, Shardlow D, Stead D et al. Sequential mechanical and pharmacological thromboprophylaxis in the surgery of hip fractures. A pilot study. Int Orthop 1997;21:259-261 (Pubitemid 27464622)
6. (SIGN). SIGN. Prophylaxis of venous thromboembolism: a national clinical guideline. 2002; SIGN Publication No. 62. Available at: http://www.sign.ac.uk.
7. Salvati EA, Pellegrini VD Jr, Sharrock NE, Lotke PA, Murray DW, Potter H et al. Recent advances in venous thromboembolic prophylaxis during and after total hip replacement. J Bone Joint Surg Am 2000;82:252-270
8. Haas S, Breyer HG, Bacher HP, Fareed J, Misselwitz F, Victor N et al, on behalf of the ECHOS Trial Group. Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial). Int Angiol 2006;25:335-342
9. Hitos K, Fletcher JP. Venous thromboembolism and fractured neck of femur. Thromb Haemost 2005;94:991-996 (Pubitemid 41645940)
10. Hitos K, Fletcher JP. Venous thromboembolism following total knee arthroplasty. Int Angiol 2006;25:343-351 (Pubitemid 46350990)
11. White RH, Romano PS, Zhou H, Rodrigo J, Bargar W. Incidence and time course of thromboembolic outcomes following total hip or knee athroplasty. Arch Intern Med 1998;158:1525-1531 (Pubitemid 28340985)
12. Dahl OE, Gudmundsen TE, Haukeland L. Late occurring clinical deep vein thrombosis in joint-operated patients. Acta Orthop Scand 2000;71:47-50. (Pubitemid 30150555)
13. Arnesen H, Dahl OE, Aspelin T, Seljeflot I, Kierulf P, Lyberg T. Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin. J Thromb Haemost 2003;1:971-975
14. Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 2001;358:9-15. (Pubitemid 32709732)
15. Eriksson BI, Bergqvist D, Kalebo P, Dahl OE, Lindbratt S, Bylock A et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: The METHRO II randomised trial. Lancet 2002;360:1441-1447 (Pubitemid 35356320)
16. Eriksson BI. Clinical experience of melagatran/ximelagatran in major orthopaedic surgery. Thromb Res 2003;109 Suppl 1:S23-29.
17. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Mouret P, Rosencher N et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 2003;89:288-296 (Pubitemid 36227281)
18. Bergqvist D, Hull RD. Effective thromboprophylaxis administered close to the time of major orthopedic surgery: a review. Am J Orthop 2006;35:226-230
19. Colwell CW, Jr., Kwong LM, Turpie AG, Davidson BL. Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic surgery. J Arthroplasty 2006;21:36-45.
20. Rubin GL, Schofield WN, Dean MG, Shakeshaft AP. Appropriateness of red blood cell transfusions in major urban hospitals and effectiveness of an intervention. Med J Aust 2001;175:354-358
21. Nilsson KR, Berenholtz SM, Garrett-Mayer E, Dorman T, Klag MJ, Pronovost PJ. Association between venous thromboembolism and perioperative allogeneic transfusion. Arch Surg 2007;142:126-132 (Pubitemid 46294131)
22. Cushner FD. Bleeding associated with thromboprophylaxis: a multifactorial issue. Orthopedics 2003;26:s251-254.
23. Cushner FD, Friedman RJ. Blood loss in total knee arthroplasty. Clin Orthop Relat Res 1991;269:98-101.
24. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-2775 (Pubitemid 351930851)
25. Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Int Angiol 2006;25:101-161